ArticleBMC cancer2026
Predicting response to neoadjuvant hormonal therapy and prognostic outcomes in high-risk prostate cancer using MRI-based radiomics.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to develop and validate an MRI-based radiomics model for predicting complete response (CR), defined as either pathological complete response (pCR) or minimal residual disease (MRD), to neoadjuvant hormonal therapy (NHT) and to assess its prognostic value in patients with high-risk prostate cancer (HRPCa).
methodsThis retrospective study included 140 patients with HRPCa who underwent NHT followed by radical prostatectomy at Huadong Hospital. Radiomic features were extracted from preoperative apparent diffusion coefficient (ADC) maps and T2-weighted imaging(T2WI) derived from multiparametric MRI. Feature selection was performed using appropriate statistical methods, and predictive models were constructed using various machine learning classifiers. The performance of the radiomics signature and a combined model integrating clinical MRI and pathological features were evaluated.
resultsFor CR prediction, one clinical MRI feature (seminal vesicle invasion), one pathological feature (cribriform adenocarcinoma), and thirteen radiomics features (eight from ADC and five from T2WI) were ultimately selected. The combined model achieved AUC of 0.932 (0.884–0.980) in the training cohort and 0.979 (0.939–1.000) in the internal validation cohort.Decision curve analysis confirmed its clinical net benefit. Furthermore, Kaplan-Meier analysis revealed that patients predicted by the model to have a higher probability of CR experienced significantly better disease-free survival compared to those with a lower predicted probability.
conclusionBased on a substantial sample size and rigorous internal validation, the proposed MRI-based radiomics model achieved a high Radiomics Quality Score (RQS). It shows strong potential for the non-invasive prediction of treatment response and prognosis in HRPCa, demonstrating significant clinical value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.